Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

More documents

Recommendations

Info

114Figure 3.196 Outcomes and planning 2003-2008Figure 3.197 LF at-risk populationAnnual Report on Lymphatic Filariasis 2003No. of IUs20151050.60.50.40.3million people0.20.1Population in millions2520151050Total pop.25 MAt-risk pop.22 MChapter 3 Programme implementation0% of at-risk population covered2003100755025No. IUs20042005Planned pop. coverage020062007Figure 3.198 Geographical coverage20080.0Pop. reported to haveingested drugs2.32003Figure 3.199 MDA reported coverage%1009081.2807060502003Figure 3.200 IUs with reported coverage >65%Figure 3.201 Updated mapping status10080100Total: 75 IUs32 IUs 10 IUs 33 IUsUncertain Non-endemic Endemic60%402002003
SRI LANKA115Endemicity statusEndemicNon-endemicUncertainAnnual Report on Lymphatic Filariasis 2003LF is a public health problem for Sri Lanka’s populationof more than 18 million. More than 55% of the populationis estimated to be at risk. Although there has beena significant reduction in the disease since the initiationof the control programme by the anti-filariasis campaignin 1947, it has remained static at a lower level oftransmission. There are no recent data on clinical manifestationsevaluated in all the IUs (sentinel sites). Themain activities of the campaign are annual, single-doseMDA using DEC plus albendazole, detection of microfilaraemiain the sentinel sites and selective treatmentof mf positives with multi-dose DEC, management oflymphoedema patients to prevent disability, entomologicalinvestigation for transmission in the sentinel sites,vector control and health education.The administrative division designated as an IU is thedistrict. The mapping of LF showed that out of 25 districts,eight in the western, southern and north-westernprovinces, with an estimated 9.8 million population, areconsidered at risk. The national PELF began in 1999 withdrug distribution of a twice-yearly single dose of DECalone, covering the total population of the eight IUs.In 2001, the first round of MDA with the co-administrationof DEC plus albendazole was started in the Colombodistrict with a population of 2.1 million. In 2002, all eightIUs were targeted with a reported coverage of 85.99%(range 67% to 92.4%). In the third round, in 2003, 9.8million were targeted with a reported coverage of 87.2%(range: 80.4% to 108%). The door-to-door drug distributionstrategy was used. In addition, special populationgroups were covered using a booth approach.Chapter 3 Programme implementationTable 3.32 Goal: to eliminate LF from Sri Lanka by 2007Objectives• To interrupt LF transmission• To prevent LF-associated disabilityStrategies• Annual single-dose MDA of the endemic population using DEC plusalbendazole• Selective treatment of microfilaria positives with multi-dose DEC• Management of lymphoedema sufferers to prevent disability• Introducing the community home-based disability managementprogramme in the LF-endemic areas in a phased manner• Strengthening the available facilities for surgical treatment of hydrocele
Page 1 and 2:
For further information about lymph
Page 3:
WHO/CDS/CPE/CEE/2005.52GlobalProgra
Page 7 and 8:
3Report of the Technical Advisory G
Page 9 and 10:
P R O G R A M M E H I G H L I G H T
Page 11:
I N T R O D U C T I O N7This Annual
Page 14 and 15:
10Annual Report on Lymphatic Filari
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
38Figure 3.2 Outcomes and planning
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 59 and 60:
UNITED REPUBLIC OF TANZANIA55Endemi
Page 61 and 62:
ZANZIBAR, UNITED REPUBLIC OF TANZAN
Page 63:
59AMERICAN PROGRAMME REVIEWGROUPAt
Page 66 and 67:
Page 68 and 69: 64Annual Report on Lymphatic Filari
Page 76 and 77: 72Figure 3.81 Outcomes and planning
Page 86 and 87: 82Figure 3.100 Outcomes and plannin
Page 104 and 105: 100Annual Report on Lymphatic Filar
Page 127: C H A P T E R 6FURTHER DOCUMENTATIO
Page 135 and 136: ANNUAL REPORT FOR THE NATIONAL PROG
Page 137 and 138: 1332. PROGRAMME RESOURCES2.1 Please
Page 139 and 140: 1353.3 Interruption of transmission
Page 141 and 142: 1373.3.6a Report of MDA coverage by
Page 143 and 144: 1393.3.7 Surveys in sentinel sites
Page 145 and 146: 1413.3.10 Please attach a map of th
Page 147 and 148: 1434. SERIOUS ADVERSE EXPERIENCES (
Page 149 and 150: A N N E X E SANNEX 3: LIST OF LF-EN
Page 151 and 152: 147RAPLOARPRGSAESEAROTAG-LFTDRUNDPU
Page 153 and 154: 149Drug administration and monitori
show all

Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

Create successful ePaper yourself

Delete template?

Save as template?